PRAX Company Profile and Key Details

Q: Who are the executives of PRAX?

Mr. Marcio Souza M.B.A.Pres, Chief Executive Officer & DirectorDr. Steven Petrou B.Sc. (Hons.), Ph.D.Co-Founder & Chief Scientific OfficerLauren MastrocolaVice President of Fin. & Principal Accounting OfficerMs. Alyssa J. S. WyantChief Regulatory & Quality OfficerMs. Kelly McCueChief People OfficerMs. Megan T. SniecinskiChief Bus. OfficerMr. Timothy Edwin KellyChief Financial Officer & TreasurerDr. Karl Hansen Ph.D.Chief Technical Operations OfficerMr. Alex Nemiroff J.D.Gen. Counsel & Sec.

NASDAQ : PRAX

Praxis Precision Medicines

$305.62

2.28+0.75%

At Close 4:00 PM

72.23

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Praxis Precision Medicines, Inc. (PRAX) stock surged +0.75%, trading at $305.62 on NASDAQ, up from the previous close of $303.34. The stock opened at $301.51, fluctuating between $297.27 and $311.54 in the recent session.

Stock Snapshot

303.34

Prev. Close

6.46B

Market Cap

297.265

Day Low

-23.56

P/E Ratio

-12.97

EPS (TTM)

-12.27

Cash Flow per Share

301.51

Open

21.14M

Number of Shares

311.54

Day High

93.92%

Free Float in %

7.69

Book Value

591.06K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Feb 05, 2026	301.51	311.54	297.27	305.62	593.38K
Feb 04, 2026	311.75	313.00	288.57	303.34	491.54K
Feb 03, 2026	311.50	325.22	306.00	310.52	509.23K
Feb 02, 2026	307.43	318.18	304.03	309.11	587.5K
Jan 30, 2026	315.00	319.13	309.12	314.00	658.98K
Jan 29, 2026	309.45	319.56	304.08	314.28	402.37K
Jan 28, 2026	323.00	323.40	308.74	309.92	606.68K
Jan 27, 2026	290.00	315.91	289.50	314.75	600.51K
Jan 26, 2026	305.98	306.00	289.72	294.04	620.46K
Jan 23, 2026	304.20	318.00	298.38	311.71	553.48K
Jan 22, 2026	312.79	319.58	299.19	304.38	430.23K
Jan 21, 2026	322.82	326.83	305.69	312.60	615.12K
Jan 20, 2026	307.20	326.06	307.20	324.08	502.89K
Jan 16, 2026	299.07	326.91	295.47	317.25	563.21K
Jan 15, 2026	300.32	305.68	294.29	297.74	757.87K
Jan 14, 2026	282.95	306.16	279.04	298.46	655.73K
Jan 13, 2026	276.00	281.56	270.00	280.83	519.4K
Jan 12, 2026	283.00	283.04	266.93	275.74	516.74K
Jan 09, 2026	291.96	305.21	285.99	288.45	671.29K
Jan 08, 2026	285.22	302.34	282.00	294.38	786.09K

Contact Details

Boston, MA 02110

United States

https://www.praxismedicines.com 617 300 8460

About Company

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Stock Peers

ARGX

-30.56-3.59%

argenx SE$820.31 REGN

-8.43-1.09%

Regeneron Pharmaceuticals, Inc.$766.63 UTHR

-3.66-0.76%

United Therapeutics Corporation$478.93 MDGL

-15.19-3.17%

Madrigal Pharmaceuticals, Inc.$463.42 VRTX

-11.71-2.49%

Vertex Pharmaceuticals Incorporated$458.81 ALNY

-20.72-5.89%

Alnylam Pharmaceuticals, Inc.$331.24 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 KRYS

-1.49-0.55%

Krystal Biotech, Inc.$267.64 SGEN

-0.16-0.07%

Seagen Inc.$228.74 CDTX

Cidara Therapeutics, Inc.$221.38

Company Overview

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) closed at $305.62 USD, gaining $2.28 (0.75%) from the previous close of $303.34. The stock is currently mid-range between its 52-week high and low $26.70 and $326.91. With a market capitalization of about $6.46 billion, Praxis Precision Medicines, Inc. is classified as a mid-cap and shows higher-than-market volatility (beta ~2.90). Key stats such as the average daily volume over the past year has been around 768.50 thousand shares, in line with its 52-week average. Headquartered in Boston, MA, Praxis Precision Medicines, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Marcio Silva De'Souza, the company employs approximately 116 people and listed since October 16, 2020. Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance.

Technical Performance

PRAX has shown sold momentum, gaining 17.53% over the past week and 70.58% over the past quarter, though year-to-date performance is up 9.95%. Short-term trend indicators are bearishly aligned (SMA20 0.51%, SMA50 12.03%, SMA200 153.14%). The stock’s 14-day RSI is 54.96 (neutral), while the ATR of 18.38 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -6.51% below its high and over 1044.64% above its low. Average 10-day trading volume of 563.41 thousand shares is below the 3-month average of 732.94 thousand, indicating normal recent market interest.

Valuation Metrics

Praxis Precision Medicines, Inc. trades at a P/E ratio of -24.23, slightly below the S&P 500 average, with a price-to-sales ratio of 852.86 and a price-to-book ratio of 19.26 reflecting a rich premium to book value. The P/FCF stands at -27.87, also above market averages. Compared to sector medians, Praxis Precision Medicines, Inc. P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Dividend & Fair Value

Praxis Precision Medicines, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $13.35. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Praxis Precision Medicines, Inc. generated EPS of -$12.90 over the past year. Five-year average earnings growth is 8.54%. Wall Street analysts project EPS growth of 16.28% annually over the next five years. The latest quarter delivered EPS of -$3.36. The next quarter is forecast at -$3.10. Next year's EPS is expected at $34.53. Analyst sentiment is bullish. Analyst rating data shows there are 5 Strong Buy ratings, 33 Buy ratings, 1 Hold ratings, 0 Sell rating and 4 Strong Sell ratings. Price targets range from $1.25 thousand to $73.00. The high target offers 307.37% upside. The low target suggests -76.11% downside. The mean target is $316.47. This offers 3.55% upside. Praxis Precision Medicines, Inc. earnings surprise history is a mixed track record. The quarter that ended November 05, 2025, missed forecasts by -2.49%. The prior quarter beat by -2.65%. Over the last six quarters, Apple has recorded several small beats. These include -99.93% in August 13, 2024.

Shareholding & Insider Activity

Praxis Precision Medicines, Inc. has 21.05 million shares outstanding. The public float is 15.64 million shares, elevated short interest at 11.10% of float. This equals 2.33 million shares. The short ratio is 4.23 days. Institutional investors hold 113.28% of the float. Insiders own 0.15%. Vitorovic Stefan holds 2.94 million shares, Adage Capital Management, L.P. has 2.06 million shares and MITCHELL DEAN J has 75.00 thousand shares. Over the past six months, insider transactions show net selling. They sold 30.44 thousand shares across 3 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Praxis Precision Medicines generated $2.45M in revenue, or $0.37 per share. Gross margin was 82.35%, operating margin -5164.41%, and net profit margin -5037.88%. Returns are negative, with ROA at -140.17% and ROE at -176.95%.
On valuation metrics, Praxis Precision Medicines trades at a P/E of -24.23, P/S of 852.86 and P/B of 19.26. The current ratio is 5.18 and quick ratio is 5.18. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -45.75 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.00, supported by a cash flow-to-debt ratio of -523.49.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Praxis Precision Medicines posted revenue of $2.45M, down slightly from $0.00 in the prior quarter. Gross profit was $2.02M (margin 82.35%). Operating income was - $126.37M (margin -5164.4%). Net income was- $123.28M (EPS - $18.69).
The company ended the quarter with $81.30M in cash and short-term investments, a total debt of $2.50M, and net debt of - $78.81M. Total assets were $87.95M, with equity of $69.67M. Financials further reflected weakness, with operating cash flow of - $111.14M, free cash flow of - $111.19M, and capital expenditures of - $50.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that Praxis Precision Medicines, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 4.57%, with price expected at $319.58 by February 18, 2026, within a range of $307.04 to $330.85 3-Month Outlook: Projected fall of -44.12%, reaching $170.78 by May 05, 2026, with a range of $166.74 to $174.33. 1-Year Outlook: Projected gain of 17.83%, with price at $360.10 by February 04, 2027, within a range of $340.33 to $378.13.

Key Takeaways

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) shares are flat 9.95% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Praxis Precision Medicines, Inc. trading at a premium to the broader market with a P/E of -24.23. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $215.77, suggesting -29.4% downside. Our AI forecast model points to short-term strength (4.57% over two weeks), a medium-term fall (-44.12% over three months), and a longer-term gain (17.83% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Praxis Precision Medicines, Inc. (PRAX) stock price?

Praxis Precision Medicines, Inc. (NASDAQ: PRAX) stock price is $305.62 in the last trading session. During the trading session, PRAX stock reached the peak price of $311.54 while $297.27 was the lowest point it dropped to. The percentage change in PRAX stock occurred in the recent session was 0.75% while the dollar amount for the price change in PRAX stock was $2.28.

PRAX's industry and sector of operation?

The NASDAQ listed PRAX is part of Biotechnology industry that operates in the broader Healthcare sector. Praxis Precision Medicines, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of PRAX?

Mr. Marcio Souza M.B.A.
Pres, Chief Executive Officer & Director
Dr. Steven Petrou B.Sc. (Hons.), Ph.D.
Co-Founder & Chief Scientific Officer
Lauren Mastrocola
Vice President of Fin. & Principal Accounting Officer
Ms. Alyssa J. S. Wyant
Chief Regulatory & Quality Officer
Ms. Kelly McCue
Chief People Officer
Ms. Megan T. Sniecinski
Chief Bus. Officer
Mr. Timothy Edwin Kelly
Chief Financial Officer & Treasurer
Dr. Karl Hansen Ph.D.
Chief Technical Operations Officer
Mr. Alex Nemiroff J.D.
Gen. Counsel & Sec.

How PRAX did perform over past 52-week?

PRAX's closing price is 1,044.64% higher than its 52-week low of $26.70 where as its distance from 52-week high of $326.91 is -6.51%.

How many employees does PRAX have?

Number of PRAX employees currently stands at 116.

Link for PRAX official website?

Official Website of PRAX is: https://www.praxismedicines.com

How do I contact PRAX?

PRAX could be contacted at phone 617 300 8460 and can also be accessed through its website. PRAX operates from 99 High Street, Boston, MA 02110, United States.

How many shares of PRAX are traded daily?

PRAX stock volume for the day was 591.06K shares. The average number of PRAX shares traded daily for last 3 months was 768.5K.

What is the market cap of PRAX currently?

The market value of PRAX currently stands at $6.46B with its latest stock price at $305.62 and 21.14M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	116
Beta	2.88
Sales or Revenue	$2.45M
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

PRAX Company Profile and Key Details

Praxis Precision Medicines

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Company Overview

Technical Performance

Dividend & Fair Value

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Earnings & Analyst Outlook

Key Takeaways

Price Forecast & Outlook

Valuation Metrics